Considerations for advanced ovarian cancer mutation testing in a clinical setting
| Question | Variables | Agreement (%) | Disagreement (%) |
| Statements that achieved consensus | |||
| Regarding molecular biomarker testing for advanced ovarian cancer patients, how do you agree or disagree with the following statements? | Testing for BRCA mutation/homologous recombination deficiency status should be performed as soon as a tissue sample is available | 100.0 | 0.0 |
| Additional core biopsies should be collected for patients receiving neoadjuvant treatment to enable immediate biomarker testing | 94.0 | 6.0 | |
| It is acceptable to start first-line systemic therapy before ordering tests for BRCA/homologous recombination deficiency | 94.0 | 6.0 | |
| Both tests (BRCA mutation and homologous recombination deficiency) should be ordered at the same time upfront | 87.0 | 13.0 | |
| A histological diagnosis of high-grade ovarian cancer is needed before tumor testing for homologous recombination deficiency | 81.0 | 19.0 | |
| Regarding appropriate HR tests for advanced ovarian cancer patients, how do you agree or disagree with the following statements? | It is also acceptable for the use of other academic homologous recombination deficiency tests provided a previous validation at least in a randomized clinical trial cohort | 100.0 | 0.0 |
| Any commercially available tests, regardless as to whether they have been validated in clinical trials, can be used for guiding treatment decisions | 13.0 | 87.0 | |
| Homologous recombination deficiency testing should not be replaced by homologous recombination mutation panel testing | 94.0 | 6.0 | |
| A separate test for somatic BRCA is not required, as this can be collected in the homologous recombination test | 87.5 | 12.5 | |
| Statements that did not achieve consensus | |||
| Regarding molecular biomarker testing for advanced ovarian cancer patients, how do you agree or disagree with the following statements? | When possible, methylation status should be performed | 50.0 | 50.0 |
| Patients with all histological subtypes of ovarian cancer, including mucinous ovarian cancer that shows a good response to platinum-based chemotherapy, should be offered somatic tumor testing for homologous recombination deficiency | 25.0 | 75.0 | |
| Regarding sequence of biomarkers testing for advanced ovarian cancer patients, how do you agree or disagree with the following statement? | Homologous recombination deficiency should only be offered in high-grade serous or endometrioid ovarian cancer subtypes | 37.0 | 63.0 |
Bold values indicate the achieved (≥80% agreement or disagreement) or nearest-to-consensus across each statement.